Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Heae Surng Park



Author of

  • +

    P1.02 - Biology/Pathology (ID 614)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Biology/Pathology
    • Presentations: 1
    • +

      P1.02-024 - Correlation of Maximal Tumor Diameter between Pathology Specimen and CT in Nonsmall Cell Lung Cancer: A Pilot Study (ID 8201)

      09:30 - 09:30  |  Presenting Author(s): Heae Surng Park

      • Abstract
      • Slides

      Background:
      Tumor size has been recognized as an important prognostic factor. In renal tumor, CT imaging generally overestimates pathological tumor size. However, systematic correlation of tumor size between pathology and radiology in lung cancer has not been studied yet. Herein, we compared the maximal tumor diameter between surgically resected fresh lung tissue and chest CT.

      Method:
      Our study included 75 surgically resected nonsmall cell lung cancer specimens submitted in a fresh state. Pathologic tumor size (PTS) was obtained by measuring the largest cross-sectional tumor diameters in the fresh specimen. Radiologic tumor size (RTS) was retrospectively measured in axial (RTSax) and reconstructed oblique (RTSrecon) image of chest CT. Tumors larger than 4 cm, tumors with uncertain margins owing to underlying lung fibrosis or pneumonia, and tumors sectioned in formalin-fixed state were excluded.

      Result:
      The mean PTS, RTSax, and RTSrecon with standard deviation were 2.1cm ± 0.815, 2.068cm ± 0.822, and 2.26cm ± 0.871, respectively. PTS and RTrecon was significantly different (PTS-RTSrecon: -1.179±0.404, p<0.001), while there was no statistically significant difference between PTS and RTSax. Scatter plot and linear regression analysis demonstrated a strong positive correlation between PTS and RTS (PTS = 0.395+0.824xRTSax, p<0.001; PTS=0.233+0.818xRTSrecon, p<0.001). The intraclass correlation coefficient (ICC) between PTS and RTSax was 0.832 (95% confidence interval, 0.747-0.890). The ICC between PTS and RTSrecon was 0.884 (95% confidence interval, 0.822-0.925). There was no significant difference between PTS and RTS associated with histologic subtype, specimen type, warm ischemic time, predominant lepidic histology, pleura invasion, and gross feature.

      Conclusion:
      Both RTSax and RTSrecon were significantly correlated with PTS. Reliability analysis showed that RTSrecon correlated with PTS slightly better than RTSax, although RTSrecom tended to overestimate PTS. Further study with larger sample size would be needed.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P1.05 - Early Stage NSCLC (ID 691)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Early Stage NSCLC
    • Presentations: 1
    • +

      P1.05-014 - Efficacy of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small Cell Lung Cancer  (ID 9026)

      09:30 - 09:30  |  Author(s): Heae Surng Park

      • Abstract

      Background:
      This study aimed to identify the predictive factors for prognosis of stage IB NSCLC and determine the efficacy of adjuvant chemotherapy on recurrence and survival.

      Method:
      This is a retrospective study with reviewing the electronic medical records. We enrolled 89 patients with stage IB NSCLC who underwent complete resection surgery at Gangnam Severance Hospital from Jan 2008 to Dec 2014. As per the National Comprehensive Cancer Network guidelines, patients were considered to be at high risk when they showed poorly differentiated tumors, lymphovascular invasion, tumor size > 4 cm, and visceral pleural invasion (VPI). We evaluated disease-free survival and overall survival.

      Result:
      Among the 89 patients, 62 underwent adjuvant chemotherapy. Young patients or patients with squamous cell lung cancer received adjuvant chemotherapy frequently. Adjuvant chemotherapy was not a significant factor for disease-free survival and overall survival. Adjuvant chemotherapy did not show a significant protective effect for survival, even for high-risk patients. However, VPI was a significant risk factor for disease-free survival (hazard ratio [HR]: 7.051; 95% confidence interval [CI]: 1.570–31.659; P-value = 0.011) and overall survival (HR: 8.289; 95% CI: 1.036–66.307; P-value = 0.046), even after adjustment for various factors.

      Conclusion:
      Adjuvant chemotherapy does not affect the prognosis of stage IB NSCLC, even in high-risk patients. Additionally, VPI is a strong prognostic factor of stage IB NSCLC.